Analysts have recently evaluated GoodRx Holdings and provided 12-month price targets. The average target is $4.16, accompanied by a high estimate of $6.00 and a low estimate of $2.75. This current ...
GoodRx Holdings Inc. (NASDAQ:GDRX) is one of the oversold stocks to buy now. On January 5, Bank of America analyst Allen Lutz ...
Surescripts is teaming up with Good Rx to surface key prescription discounts to consumers. | SAN FRANCISCO — Surescripts is ...
Surescripts®, the nation’s leading health intelligence network, introduces its Patient Experience product, Script Corner™, to transform the medication experience and empower patients by bringing ...
JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings (NASDAQ:GDRX) following the company’s first-quarter earnings. Gill reaffirmed an Overweight rating on the stock and ...
GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results